Biopharma industry commits to working with regulatory agencies on COVID-19 vaccines
A statement from biopharmaceutical industry groups has said they plan to work with regulatory agencies to gather data on COVID-19 vaccines.
List view / Grid view
News
COVID-19 antibody therapy shows promise in Phase II/III trial
CT-P59, a monoclonal antibody therapy for COVID-19, was found to be particularly effective at reducing recovery times in moderate COVID-19 patients aged 50 plus.
Antibiotics market set to generate revenue of $58,800 million by 2027
A new report has predicted that the global antibiotics market will grow at a CAGR of four percent from 2020-2027.
Pfizer COVID-19 vaccine set to generate sales of $30 billion
Over a six year period, the Pfizer-BioNTech COVID-19 vaccine is expected to lead inoculation sales, generating $30 billion.
European Commission approves dispersible tablets to treat paediatric HIV
Marketing authorisation in the EU has been given to Tivicay (dolutegravir) dispersible tablets to treat HIV in certain paediatric patients.
Phase III trial to study interferon beta therapy in COVID-19 patients initiated
Synairgen's interferon beta therapy is being studied as a potential COVID-19 treatment in a Phase III trial as the first patient is dosed.
First patient dosed with COVI-VAC, an intranasal COVID-19 vaccine candidate
The trial will assess the safety and immunogenicity of a single intranasal dose of COVI-VAC in 48 healthy volunteers in the UK.
EMA receives authorisation application for AstraZeneca COVID-19 vaccine
The EMA has received a conditional marketing authorisation application for the Oxford-AstraZeneca COVID-19 vaccine.
CDMO awarded $850,000 contract for development of Acute Cannabinoid Overdose treatment
Under the contract, IRISYS LLC will develop a new, injectable formulation of drinabant that can rapidly and effectively reverse the symptoms of Acute Cannabinoid Overdose (ACO).
Amgen sets target of achieving carbon neutrality by 2027
Amgen has set out the company's seven-year environmental sustainability plan to achieve carbon neutrality by 2027.
Baxter BioPharma Solutions to manufacture Novavax’s COVID-19 vaccine
The agreement is expected to advance the commercial-scale manufacturing of the NVX-CoV2373 to enable it to be distributed across Europe following regulatory approval.
FDA approves Phase III trial of synthetic biological COVID-19 treatment
The international Phase III trial will evaluate whether a 14 day course of carrimycin can improve outcomes for COVID-19 patients with severe symptoms.
FDA monitoring impact of SARS-CoV-2 mutations
The FDA has alerted clinical laboratory staff and healthcare providers that it is monitoring the potential impact of SARS-CoV-2 mutations, including the UK variant.
Risankizumab trials show higher clinical remission in patients with Crohn’s disease
Two Phase III trials have shown that two doses of risankizumab met the primary endpoints in patients with Crohn's disease.
Value of pharma’s M&A deals remain high, despite COVID-19
Analysts say M&A deals continue to be a core driver of pharma/biopharma industry growth and that 2021 will likely be another year of high deal value.
